Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma

Arnold S Freedman, MD
Jon C Aster, MD
Section Editors
Andrew Lister, MD, FRCP, FRCPath, FRCR
Julie R Park, MD
Deputy Editor
Alan G Rosmarin, MD


Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma characterized by the translocation and deregulation of the c-MYC gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic (African), sporadic (non-endemic), and immunodeficiency-associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms as described below.

BL and Burkitt leukemia are considered different manifestations of the same disease in the World Health Organization (WHO) classification of hematologic malignancies; "Burkitt-like lymphoma with 11q aberration" and "High-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement" have been proposed as separate entities distinct from BL [1,2]. In addition, the WHO provides an overlap category termed "High-grade B cell lymphoma, not otherwise specified." Some tumors in this group were previously classified as "Burkitt-like" lymphoma. (See "Classification of the hematopoietic neoplasms".)

The epidemiology, clinical features, pathology, and diagnosis of BL will be reviewed here. The pathobiology and treatment of BL are discussed separately, as is a general approach to the diagnosis, staging, and prognosis of the lymphomas. (See "Pathobiology of Burkitt lymphoma" and "Treatment of Burkitt leukemia/lymphoma in adults" and "Clinical presentation and diagnosis of non-Hodgkin lymphoma" and "Evaluation and staging of non-Hodgkin lymphoma".)


The exact worldwide incidence of Burkitt lymphoma (BL) is not known, as collection of these types of epidemiologic data is limited by a lack of resources that are needed for case ascertainment and accurate diagnosis in the developing countries that have the highest apparent incidence (eg, equatorial Africa) [3]. For epidemiologic and diagnostic purposes, cases of BL are generally divided into three distinct clinical forms: endemic (African), sporadic (non-endemic), and immunodeficiency-associated. The endemic and sporadic clinical variants of BL differ geographically.

Endemic – The endemic variant is found in equatorial Africa and New Guinea. The incidence of BL in Africa is approximately 50-fold higher than that seen in the United States (US) [4]. BL accounts for 30 to 50 percent of all childhood cancer in equatorial Africa with an estimated incidence of 3 to 6 cases per 100,000 children per year [3]. The peak incidence occurs in children age four to seven years, and the male:female ratio is approximately 2:1.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 14, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
  2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.
  3. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012; 156:744.
  4. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008; 123:2658.
  5. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.
  6. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.
  7. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.
  8. Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.
  9. Boerma EG, van Imhoff GW, Appel IM, et al. Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer 2004; 40:2781.
  10. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.
  11. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116:5600.
  12. Qian J, Wang Q, Dose M, et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 2014; 159:1524.
  13. Meng FL, Du Z, Federation A, et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 2014; 159:1538.
  14. Robbiani DF, Deroubaix S, Feldhahn N, et al. Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell 2015; 162:727.
  15. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004; 104:3009.
  16. Falini B, Fizzotti M, Pileri S, et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997; 8 Suppl 2:101.
  17. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824.
  18. Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986; 83:2984.
  19. Lenoir GM, Preud'homme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature 1982; 298:474.
  20. Kaiser-McCaw B, Epstein AL, Kaplan HS, Hecht F. Chromosome 14 translocation in African and North American Burkitt's lymphoma;. Int J Cancer 1977; 19:482.
  21. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707.
  22. Haralambieva E, Banham AH, Bastard C, et al. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples. Br J Haematol 2003; 121:49.
  23. Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1988; 85:2748.
  24. Carroll WL, Yu M, Link MP, Korsmeyer SJ. Absence of Ig V region gene somatic hypermutation in advanced Burkitt's lymphoma. J Immunol 1989; 143:692.
  25. Klein U, Klein G, Ehlin-Henriksson B, et al. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med 1995; 1:495.
  26. Chapman CJ, Mockridge CI, Rowe M, et al. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 1995; 85:2176.
  27. Chapman CJ, Zhou JX, Gregory C, et al. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood 1996; 88:3562.
  28. Capello D, Carbone A, Pastore C, et al. Point mutations of the BCL-6 gene in Burkitt's lymphoma. Br J Haematol 1997; 99:168.
  29. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991; 138:149.
  30. Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 2006; 107:1084.
  31. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.
  32. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.
  33. Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014; 4.
  34. Haralambieva E, Schuuring E, Rosati S, et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer 2004; 40:10.
  35. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.
  36. Yano T, van Krieken JH, Magrath IT, et al. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 1992; 79:1282.